

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7566739

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
YOUNG SIK JUNG	12/16/2015
SOO BONG HAN	12/09/2015
CHONG KYO LEE	12/10/2015
HAE SOO KIM	12/15/2015
JIN SOO SHIN	12/16/2015
YASHWARDHAN RADHAMOHAN MALPANI	12/16/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
<b>Street Address:</b>	100 JANG-DONG YUSEONG-GU
<b>City:</b>	DAEJEON-SI
<b>State/Country:</b>	KOREA, REPUBLIC OF
<b>Postal Code:</b>	305-343
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	9951058
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)812-1277
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6174304740
<b>Email:</b>	sneha.khunti@mcneillbaur.com, docketing@mcneillbaur.com
<b>Correspondent Name:</b>	MCNEILL BAUR PLLC
<b>Address Line 1:</b>	125 CAMBRIDGE PARK DRIVE
<b>Address Line 2:</b>	SUITE 301
<b>Address Line 4:</b>	CAMBRIDGE, MASSACHUSETTS 02140
<b>ATTORNEY DOCKET NUMBER:</b>	01248-0007-01US
<b>NAME OF SUBMITTER:</b>	SNEHA KHUNTI
<b>SIGNATURE:</b>	/Sneha Khunti/
<b>DATE SIGNED:</b>	09/29/2022

**Total Attachments: 4**

source=2015-12-09\_01248-0007-01US\_Assignment-Inventors to KRICT#page1.tif

source=2015-12-09\_01248-0007-01US\_Assignment-Inventors to KRICT#page2.tif

source=2015-12-09\_01248-0007-01US\_Assignment-Inventors to KRICT#page3.tif

source=2015-12-09\_01248-0007-01US\_Assignment-Inventors to KRICT#page4.tif

**ASSIGNMENT**

WHEREAS, Young Sik Jung, Soo Bong Han, Chong Kyo Lee, Hae Soo Kim, Jin Soo Shin, and Yashwardhan Radhamohan Malpani, hereinafter called the "Assignors", have made an invention entitled NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT, for a full description of which reference is here made to an application for Patent filed in the Korean Intellectual Property Office on December 14, 2012 and assigned Application No. 10-2012-0146081, an application for Patent filed in the Korean Intellectual Property Office on December 16, 2013 and assigned Application No. 10-2013-0156409, and an application for Letters Patent of the United States filed on June 11, 2015 and assigned Application Serial No. 14/651,656 that claims priority to the two above-listed applications filed in the Korean Intellectual Property Office;

WHEREAS, Korea Research Institute of Chemical Technology, an entity organized and existing under the laws of Republic of Korea, having a place of business at 100 Jang-Dong Yuseong-gu, Daejeon-si 305-343 Republic of Korea, hereinafter called the "Assignee", desires to acquire the entire right, title and interest in and to the invention and the patent applications identified above, and all patents which may be obtained for said invention, as set forth below;

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00), and other valuable and legally sufficient consideration, the receipt of which by the Assignors from the Assignee is hereby acknowledged, the Assignors have sold, assigned and transferred, and by these presents do sell, assign and transfer to the Assignee, the entire right, title and interest for the United States in and to the invention and the patent applications identified above, and any patents that may issue for said invention in the United States; together with the entire right, title and interest in and to said invention and all patent applications and patents issuing therefrom in all countries foreign to the United States, including the full right to claim for any such application all benefits and

priority rights under any applicable convention; together with the entire right, title and interest in and to all continuations, divisions, renewals and extensions of any of the patent applications and patents defined above; together with the right to recover all damages, including, but not limited to, a reasonable royalty, by reason of past, present, or future infringement or any other violation of patent or patent application rights; to have and to hold for the sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignors hereby confirm their prior sale, assignment and transfer, pursuant to an internal regulation of Assignee regarding in-service inventions by its employees, which includes Assignors, and by prior written deed of assignment, of their entire right, title and interest in and to the invention and the patent applications identified above to the Assignee.

In the event that Assignors did not accomplish such sale, assignment and transfer by virtue of such internal regulation and written deed of assignment, Assignors hereby sell, assign, and transfer their entire right, title and interest to the Assignee as of the days of filing the patent applications identified above.

The Assignors hereby covenant and agree, for both the Assignors and the Assignors' legal representatives, that the Assignors will assist the Assignee in the prosecution of the patent applications identified above; in the making and prosecution of any other patent applications that the Assignee may elect to make covering the invention identified above; in vesting in the Assignee like exclusive title in and to all such other patent applications and patents; and that the Assignors will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

The Commissioner of Patents and Trademarks is hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignors have executed this agreement.

DATE:

Dec 16, 2015

Young Sik Jung

WITNESSED:

DATE: \_\_\_\_\_

DATE: \_\_\_\_\_


DATE: Dec. 09, 2015 

Soo Bong Han

WITNESSED: \_\_\_\_\_

DATE: \_\_\_\_\_

DATE: \_\_\_\_\_


DATE: Dec. 10, 2015 

Chong Kyo Lee

WITNESSED: \_\_\_\_\_

DATE: \_\_\_\_\_

DATE: \_\_\_\_\_


DATE: Dec 15, 2015 

Hae Soo Kim

WITNESSED: \_\_\_\_\_

DATE: \_\_\_\_\_

DATE: \_\_\_\_\_


DATE: Dec 16, 2015 

Jin Soo Shin

WITNESSED: \_\_\_\_\_

DATE: \_\_\_\_\_

DATE: \_\_\_\_\_

DATE: Dec 16, 2015 

Yashwardhan Radhamohan Malpani

WITNESSED: \_\_\_\_\_

DATE:

\_\_\_\_\_

DATE:

\_\_\_\_\_